NCT05547087View on ClinicalTrials.gov

A Dose Finding Study of VN-0200

PHASE2CompletedINTERVENTIONAL
Enrollment

342

Participants

Timeline

Start Date

October 13, 2022

Primary Completion Date

April 11, 2023

Study Completion Date

February 15, 2024

Conditions
Respiratory Syncytial Virus Infections
Interventions
BIOLOGICAL

VN-0200

VN-0200 (antigen: VAGA-9001a, adjuvant: MABH-9002b) administered as an intramuscular injection; 2 shots in 4 weeks.

Trial Locations (3)

812-0025

SOUSEIKAI PS Clinic, Hakata

130-0004

SOUSEIKAI Sumida Hopital, Sumida City

861-4157

SOUSEIKAI Nishi-Kumamoto Hospital, Kumamoto

Sponsors

Lead Sponsor

Daiichi Sankyo
All Listed Sponsors
lead

Daiichi Sankyo

INDUSTRY